Table 2.
Efficacy of approved therapies for HIV-1 pre-exposure prophylaxis.
| Clinical trial (phase) | Recruited individuals | Trial arm | HIV infection no./patient no. | Person-yearsa | Incidence rateb | P-value | Ref. |
|---|---|---|---|---|---|---|---|
| DISCOVER (phase 3) | HIV-negative or transgender MSM | TAF + FTC | 7/2694 | 8756 | 0.16% | >0.05 | 50 |
| TDF + FTC | 15/2693 | 0.34% | |||||
| iPrEx (phase 3) | HIV-negative or transgender MSM | TDF + FTC | 38/1251 | 3324 | NA | NA | 51 |
| Placebo | 72/1248 | NA | |||||
| MTN-020–ASPIRE (phase 3) | HIV-negative women (18–45 years) | Dapivirine vaginal ring | 71/1313 | 4280 | 3.3% | 0.046 | 77 |
| Placebo | 97/1316 | 4.5% | |||||
| Ring (phase 3) | HIV-negative women (18–45 years) | Dapivirine vaginal ring | 77/1307 | 1888 | 4.1% | 0.04 | 78 |
| Placebo | 56/652 | 6.1% |
MSM: men who have sex with men.
a
The person-years of follow-up are summarized for individual studies.
b
Incidence rate equals the number of HIV-1 infections divided by person-years of follow-up. P-value indicates the statistical difference of incidence rates between the intervention arm and the placebo arm.